Nephrology

Atrasentan significantly reduces proteinuria in patients with IgA nephropathy, showing a 36.1% reduction compared to placebo at 36 weeks.

Hosts break down the FLOW trial, take a deep dive into secondary findings, and provide insight into how this alters the perception of the role for semaglutide in management of CKD in type 2 diabetes.

Vlado Perkovic, MBBS, PhD, discusses the results of the FLOW trial and their implications for clinical practice at ERA 24.

New study finds SGLT2 inhibitors reduce proteinuria in IgA nephropathy, with greater initial eGFR dips predicting stronger treatment responses.

Semaglutide 1.0 mg reduced major kidney disease events and slowed eGFR decline in patients with type 2 diabetes and chronic kidney disease, according to the FLOW trial.

Check out this quiz on the NKF's KDOQI recommendations on nutrition in chronic kidney disease, with a focus on their guidance for protein and energy intake!

Check out this quiz on the NKF's KDOQI recommendations on nutrition in chronic kidney disease, with a focus on their guidance for micronutrient supplementation!

Study results showed systemic corticosteroids induced greater remission rates alone than in combination with other immunosuppressive treatments but were linked to adverse events.

Check out this quiz on the NKF's KDOQI recommendations on nutrition in chronic kidney disease, with a focus on their guidance for nutritional assessments!

A post hoc analysis from FIDELITY shows finerenone could significantly reduce eGFR slopes among patients at risk of worsening CKD due to a heart failure hospitalization.

Further analyses into the 2-year PROTECT trial further support the longevity of benefit with sparsentan in patients with IgAN.

The multicenter study examined the presentation and outcomes of patients with cirrhosis-related IgAN and compared clinicopathological profiles with primary IgAN.

The analysis of NHANES data revealed almost 90% of adults meet the criteria for stage 1 or greater CKM syndrome, consistent from 2011-2020.

Findings suggest the potential prognostic value of time-averaged serum uric acid for predicting disease progression in IgAN.

Proteinuria < 1 g/d is the current treatment target, but findings suggest patients with uACR between 0.3 and 1.0 g/g face a substantial risk of adverse kidney outcomes.

Results showed the prevalence and treatment patterns for IgAN in select Asian Pacific countries and regions were not commonly available.

Findings showed the light microscopy pattern of glomerular injury and the intensity of mesangial C3 deposition may refine the histological assessment of IgAN.

This month in review highlights top coverage of the latest news in nephrology, ranging from new clinical trial data in IgAN to research about kidney disease management.

Urinary cytokines GDF-15, IL-6, and EGF significantly strengthened the predictability of IgAN prognosis and may be viable biomarker candidates for disease progression.

Barratt explained findings from the phase 2b ORIGIN trial of atacicept and how it compares to current standard therapies in IgAN and other agents in the pipeline.

A single-center assessment showed patients with glomerulonephritis may face a heightened risk of primary disease recurrence up to 1 year after transplant.

KDpredict uses age, sex, eGFR, and albuminuria to calculate 1-5 year risk of kidney failure and death in chronic kidney disease, outperforming the kidney failure risk equation.

Results showed a negative correlation between serum Gd-IgA1 and kidney function but found no association with several validated IgAN prognostic risk factors.

Positive topline results showed treatment response consistent with NefIgArd findings, regardless of whether participants had previously been treated with Nefecon or placebo.

The American College of Physicians released new recommendations for the management of type 2 diabetes with inadequate glycemic control using metformin or other first-line therapies.